EMEA-002403-PIP01-18

Key facts

Active substance
Synthetic ribonucleic acid oligonucleotide directed against superoxide dismutase 1 (SOD1) messenger ribonucleic acid
Therapeutic area
Neurology
Decision number
P/0337/2018
PIP number
EMEA-002403-PIP01-18
Pharmaceutical form(s)
Solution for injection/infusion
Condition(s) / indication(s)
Treatment of amyotrophic lateral sclerosis
Route(s) of administration
Intrathecal use
Contact for public enquiries
Biogen Idec Ltd

Tel. +44 (0)1628 512749
E-mail: pip.enquiries@biogenidec.com

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating